KHK6640 Phase1 study (A Phase1 Randomized, Placebo-Controlled, Double-Blind, Repeated Dose Study of KHK6640 in Japanese Patients with Alzheimer's Disease)

Kyowa Hakko Kirin Co., Ltd.0 个研究点目标入组 5 人开始时间: 2017年3月22日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•- Previous active treatment with an AD immunotherapy in an investigational study
•- Use of another investigational drug within 16 weeks prior to the enrollment
•- Subjects who meet National Institute of Neurological Disorders and Stroke/Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS/AIREN) criteria for vascular dementia
•- Subjects with a history of presence of clinically significant seizures, brain trauma, transient ischemic attack, and/or cerebrovascular disease
•- Subjects who have evidence of infection, tumor, or other clinically significant lesions that could indicate a dementia diagnosis other than AD
•- Subjects with a presence of a neurological condition that could be contributing to cognitive impairment above and beyond that caused by the subject's AD

发起方

Kyowa Hakko Kirin Co., Ltd.